AstraZeneca transfers Myalept for Lipodystrophy to Aegerion Pharma.
AstraZeneca has announced that it has entered into a definitive agreement with Aegerion Pharmaceuticals, Inc. to divest Myalept (metreleptin for injection), an orphan product that is indicated to treat complications of leptin deficiency in patients with generalised Lipodystrophy.
Myalept is the first and only product approved in the US for the treatment of generalised Lipodystrophy and it has orphan drug designation in the US, EU, and Japan. Myalept is a recombinant analogue of human leptin, indicated in the US as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalised Lipodystrophy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins